Vascular Embolization Market Report 2026

The vascular embolization market size has grown strongly in recent years. It will grow from $3.39 billion in 2025 to $3.71 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to expansion of interventional radiology practices, increasing prevalence of vascular disorders, growth in cancer treatment procedures, improved access to catheter-based technologies, rising physician expertise in embolization.

The vascular embolization market size is expected to see strong growth in the next few years. It will grow to $5.41 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to increasing demand for targeted therapies, rising investments in interventional oncology, expansion of outpatient embolization procedures, growing adoption of advanced imaging integration, increasing focus on patient-centric treatment options. Major trends in the forecast period include increasing adoption of minimally invasive embolization procedures, rising use of advanced embolic materials, growing demand for image-guided interventions, expansion of oncology-related embolization applications, enhanced focus on procedure precision and safety.

The high prevalence of chronic kidney diseases is expected to drive growth in the vascular embolization market in the coming years. Chronic Kidney Disease (CKD) is a condition in which the kidneys undergo gradual and irreversible damage over time. Vascular embolization in CKD can be used to control bleeding from kidney tumors, arteriovenous malformations (AVMs), or complications arising from kidney biopsies or transplants, avoiding the risks associated with open surgery, particularly in patients with compromised kidney function. For instance, in June 2023, data from ZS Associates, a UK-based Kidney Research Commission, estimated that approximately 7.19 million people in the UK were affected by kidney disease in 2023, representing more than 10% of the population, with projections indicating an increase to 7.61 million by 2033. The proportion of patients in the later stages of the disease is expected to rise from 45% to 51%. Therefore, the high prevalence of chronic kidney diseases is fueling growth in the vascular embolization market.

Major companies operating in the vascular embolization market are developing innovative products, such as embolic systems, to strengthen their market position and profitability. An embolic system consists of embolic agents and delivery devices designed to intentionally block blood vessels. Vascular embolization procedures use these systems to occlude or reduce blood flow to targeted areas of the body. For instance, in October 2023, Sirtex Medical, a US-based medical device company, launched the Lava Liquid Embolic System (LES). Available in 2-mL and 6-mL volumes, Lava provides a versatile solution for controlled occlusion of target vessels in the peripheral vasculature. Its range of viscosities allows effective distal embolization of small, hard-to-reach vessels. The FDA approved the Lava LES based on its demonstrated safety and efficacy in the single-arm LAVA Study, a prospective, multicenter trial assessing acute peripheral arterial hemorrhages.

In May 2023, Stryker Corporation, a US-based medical technology company, acquired Cerus Endovascular Ltd. for an undisclosed sum. Through this acquisition, Stryker aims to expand its neurovascular and embolization portfolio by incorporating Cerus Endovascular’s CE-marked Contour Neurovascular System and Neqstent Coil-Assisted Flow Diverter, both designed for minimally invasive intrasaccular treatment of intracranial aneurysms. Cerus Endovascular Ltd. is a UK-based commercial-stage medical device company specializing in innovative endovascular solutions for aneurysm therapy.

Major companies operating in the vascular embolization market are Abbott Laboratories, Medtronic Plc., Stryker Corporation, Boston Scientific Corporation, B. Braun Melsungen AG, Kaneka Corporation, Terumo Corporation, W. L. Gore & Associates Inc., Teleflex Inc., Cook Group Incorporated, Merit Medical Systems Inc., Penumbra Inc., MicroPort Scientific Corporation, MicroVention Inc., Medikit Co Ltd., Silk Road Medical Inc., Galt Medical Corporation, Neuravi Ltd., Phenox GmbH, Spartan Micro Inc., EndoShape Inc., Shape Memory Medical Inc., Balt Group, Vascular Solutions Inc.

North America was the largest region in the vascular embolization market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vascular embolization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vascular embolization market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the vascular embolization market by increasing costs of imported catheters, embolic agents, imaging accessories, and precision delivery systems used in embolization procedures. Hospitals and specialty clinics in North America and Europe are most affected due to dependence on imported interventional devices, while Asia-Pacific faces cost pressure on advanced medical imports. These tariffs are raising procedural costs and affecting procurement planning. However, they are also promoting domestic production of embolization devices, regional manufacturing partnerships, and innovation in cost-efficient embolic technologies.

The vascular embolization market research report is one of a series of new reports that provides vascular embolization market statistics, including vascular embolization industry global market size, regional shares, competitors with a vascular embolization market share, detailed vascular embolization market segments, market trends and opportunities, and any further data you may need to thrive in the vascular embolization industry. This vascular embolization market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vascular embolization is a minimally invasive procedure that employs various materials, including coils, particles, or liquid agents, to block or restrict blood vessels in order to stop arterial bleeding. It is used to obstruct blood vessels for different purposes, such as treating tumors, reducing vascular abnormalities, or redirecting blood flow.

The primary products used in vascular embolization include embolic agents and embolization devices. Embolic agents are substances or materials introduced into targeted areas to block or occlude blood vessels, effectively treating a range of medical conditions. They are applied in procedures for conditions such as tumors, aneurysms, and arteriovenous malformations (AVMs). Embolization techniques include coiling and non-coiling devices, which are utilized in applications such as peripheral vascular diseases, oncology, urology, neurology, and more, and are employed by end users such as hospitals, specialty clinics, ambulatory surgical centers, and diagnostic centers.

The vascular embolization market consists of revenues earned by entities by providing vascular embolization techniques such as chemoembolization or radioembolization, sac packing, sandwich technique, stent-assisted coiling, and particle embolization. The market value includes the value of related goods sold by the service provider or included within the service offering. The vascular embolization market also includes sales of balloons, gelatin foam, liquid glue, liquid sclerosing agents, particulate agents, detachable coils, and push able coils. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.